VEGFA and neoplasm: The rationale underlying the combination of TACE and VEGF drugs, as seen in the TACTICS and TACTICS-L trials, can be explained by several factors: (1) potentiation of TACE efficacy via the normalization of tumor blood vessels and reduction in tumor interstitial pressure, (2) inhibition of tumor progression by blocking VEGF system signals released after TACE, and (3) constriction of embolization range due to tumor size reduction from that prior to drug administration, thus possibly preserving liver function [77,78].